US20060112438A1 - Novel culture systems for ex vivo development - Google Patents

Novel culture systems for ex vivo development Download PDF

Info

Publication number
US20060112438A1
US20060112438A1 US11/028,345 US2834505A US2006112438A1 US 20060112438 A1 US20060112438 A1 US 20060112438A1 US 2834505 A US2834505 A US 2834505A US 2006112438 A1 US2006112438 A1 US 2006112438A1
Authority
US
United States
Prior art keywords
cells
mammalian
avian
human
egg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/028,345
Other languages
English (en)
Inventor
Michael West
Karen Chapman
Irina Klimanskaya
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US11/028,345 priority Critical patent/US20060112438A1/en
Priority to US11/211,174 priority patent/US7910369B2/en
Publication of US20060112438A1 publication Critical patent/US20060112438A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/873—Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/04—Coculture with; Conditioned medium produced by germ cells

Definitions

  • This invention generally relates to cells, tissue, and organ culture technology. More particularly, the invention relates to methods for culturing and differentiating animal pluripotent stem cells and non-human mammalian embryos and fetuses.
  • hES cells have a demonstrated potential to differentiate into any and all of the cell types in the human body including complex tissues, and while genes expressed uniquely in many differentiated cell types are known allowing genetic selection and purification of populations of any cell type of interest, nevertheless, there is need for new technologies to influence the differentiation of pluripotent stem cells such as hES cells, new means of allowing the cells to differentiate in a three dimensional tissue culture environment, and novel means of purifying the target cells of interest, and techniques such as these that can be performed in SPF conditions to minimize the risk of pathogen transmission into humans.
  • the original culture of hES cells as reported by Thomson et al was accomplished by culturing the inner cell mass of human blastocysts in co-culture with feeder layer of embryonic murine fibroblasts under culture conditions well known in the art of tissue culture to generate ES cell lines.
  • the murine fibroblasts provide largely uncharacterized factors that promote the growth of ES cells while maintaining them in an undifferentiated state.
  • the embryonic murine fibroblasts are also a potential source of pathogens including uncharacterized retroviruses. Therefore, novel means of isolating, culturing, and differentiating hES cells and other cells are of great practical value.
  • avian CEFs have been shown to support the growth of murine ES cells (Yang & Petitte, 1994), and the use of avian cytokines has been described in in non-human mammalian embryonic stem cell culture, ( Poultry Science 73: 965-974), there has been no description of the possibility that avian CEFs could be useful in providing SPF support for the growth of other mammalian ES cells such as hES cells.
  • the avian egg is a relatively well-characterized structure that has evolved as a means of providing physiological support to a developing vertebrate embryo, including nutritional support, waste disposal, and gas exchange.
  • the ovum of avian species such as the domestic chicken ( Gallus domesticus ) is that part of the egg commonly called the “yolk” ( FIG. 1 ).
  • the bulk of the ovum is a colloidal suspension of nutrients while a small volume of cytoplasm is concentrated in a region approximately 3 mm in diameter called the blastodisc on the animal pole.
  • the ovum traverses the oviduct acquiring albuminous material (egg white) and finally the shell membrane and the calcified egg shell.
  • blastodisc In the case of an egg that has become fertilized by sperm subsequent to ovulation and prior to encapsulation into the shell, the blastodisc will undergo repeated rounds of karyokinesis and cytokinesis until at about the time the egg is laid, a collection of cells called the blastoderm has formed that is roughly equivalent to the stage of mammalian embryos at the blastocyst stage. Therefore, cultured avian blastodermal cells are occasionally referred to as avian embryonic stem cells (aES cells) and those from species of domestic chicken are referred to as chicken embryonic stem (cES) cells (U.S. Pat. No. 5,340,740).
  • aES cells avian embryonic stem cells
  • cES chicken embryonic stem cells
  • extraembryonic membranes begin to form that will function to support the developing embryo. As shown in FIG. 2 , these include the splanchnopleure that will form the yolk sac, the somatopleure, that will form the amnion and the chorion, and the allantoic membrane, that will eventually fuse with the chorion to form the chorioallantoic membrane. These membranes become vascularized and provide the developing embryo with nutrients from the yolk sac and gas exchange across the egg shell.
  • the avian egg provides an unusually promising environment for the cultivation of human cells.
  • novel means of culturing and maintaining hES cells, hED cells, and cells differentiated from such cells are described utilizing telolecithal or eutelolecithal eggs or cells derived from embryonated telolecithal or eutelolecithal eggs.
  • telolecithal or eutelolecithal eggs it is possible to utilize telolecithal or eutelolecithal eggs to support the in ovo development on non-human mammalian embryos and fetuses and to reconstitute embryonic stem cells and embryo-derived cells from chromatin from mammalian species.
  • the present invention provides methods for the culture of animal pluripotent stem cells and their differentiated progeny cells, tissues, and organs, and nonhuman animal embryos and fetuses.
  • this invention provides a novel method of culturing embryos, fetuses, cells, tissues, and organs in ovo in telolecithal or eutelolecithal eggs and for the culture of hES cells, hED cells, and cells differentiated from such cells in co-culture with cells derived from embryonated telolecithal or eutelolecithal eggs for numerous commercial applications that improves yield, efficiency, cost, and risk in each of the above categories.
  • the method comprises: the utilization of an unfertilized telolecithal or eutelolecithal egg of the avian or egg-laying mammal species as a culture system for the growth and differentiation of mammalian stem cells.
  • stem cells are implanted within the vitelline membranes of the telolecithal or eutelolecithal oocyte and subsequently incubated to allow the differentiation of mammalian extraembryonic membranes whereby a mammalian yolk sac splanchnospleuric membrane surrounds the avian yolk.
  • mammalian embryonic cells can be injected in ovo in juxtaposition to the vitelline membrane and incubated over time to allow the formation of a plurality of mammalian extraembryonic membranes in the avian egg, including the formation of mammalian splanchopleure, somatopleure, chorionic membrane (CAM), allantoic membrane, amniotic membrane, or yolk sac membranes.
  • mammalian extraembryonic membranes has great utility in supporting the differentiation of hES or hED cells for purposes of research or manufacture, or, in the case of non-human mammalian species, in supporting advanced development of embryos and fetuses for research or production of agricultural animals.
  • mammalian embryonic cells such as hES cells or hED cells, or cells differentiated from such cells
  • hES cells or hED cells or cells differentiated from such cells
  • mammalian embryonic cells can be injected in ovo in juxtaposition to the vitelline membrane of an embryonated avian egg to produce differentiated cells vascularized by the vitelline vascular plexus.
  • mammalian pluripotent stem cells such as hES cells or hED cells, or cells differentiated from such cells
  • hES cells or hED cells or cells differentiated from such cells
  • the vasculature of the CAM then supplies vascularization to the growing and differentiating mass of cells.
  • mammalian pluripotent stem cells are injected in the amniotic cavity, albumin, air space, allantoic cavity, extraembryonic coelom, or the yolk sac of the egg and allowed to differentiate.
  • inducers such as factors including hormones, growth factors, extracellular matrix components, or inducer cells are introduced into the avian egg with the stem cells of the above-mentioned protocols in order to influence the course of differentiation of the injected mammalian pluripotent stem cells.
  • the inducer cells of the pervious embodiment include avian SPF cells from diverse differentiated cell lineages including somatic cells obtained from the differentiation of chicken embryonic stem (cES) cells.
  • cES chicken embryonic stem
  • whole and intact nonhuman embryos and fetuses can be cultured in the avian egg with or without a shell or shell membrane (in ovo) through the injection of nonhuman embryos or embryo-derived cells into the egg in juxtaposition to the vitelline membrane.
  • Whole and intact human embryos could also be developed in ovo using the described invention, however, it is the belief of the inventors that the use of the technology for this purpose is not ethical and claims for such uses are not sought in the present invention.
  • intact non-human mammalian embryos and fetuses can be grown in ovo and used to induce the differentiation of injected mammalian pluripotent stem cells including hES and hEDC cells by injecting such hES, hED, or cells differentiated from such cells into chosen sites of the differentiating non-human animal embryo or fetus to induce the differentiation of such injected cells.
  • mammalian pluripotent stem cells including hES and hEDC cells by injecting such hES, hED, or cells differentiated from such cells into chosen sites of the differentiating non-human animal embryo or fetus to induce the differentiation of such injected cells.
  • nonhuman mammalian embryos and fetuses can be cultivated in ovo by means of the transfer of chromatin into the blastodisc of an unfertilized avian egg, where the avian oocyte is activated and induced to undergo rounds of karyokinesis and cytokinesis and subsequent development.
  • Human chromatin can also be introduced into the blastodisc of the avian egg for the purpose of reconstituting intact embryonic cells from reprogrammed chromatin, but the development of intact human embryos post gastrulation and fetuses by this means is considered unethical and claims relating to human post-gastrulation embryos or fetuses cultured in ovo are not sought in this application.
  • embryonic cells from SPF species including SPF embryonic chicken cells are used as feeder cells for the in vitro cultivation of mammalian ES cells including hES and hEDC cells in vitro or in ovo.
  • somatic cells from SPF species including SPF embryonic chicken cells are used as cells to induce the differentiation of hES or hED cells or cells differentiated from such cells.
  • the SPF inducer cells may be viable or mitotically inactivated by radiation or chemical treatment, and may be co-cultured with the human stem cells in a variety of culture conditions including in vitro and in ovo co-culture.
  • FIG. 1 is a drawing illustrating the transfer of stem cells in juxtaposition to the vitelline membrane of the unfertilized or early embryonated avian egg.
  • the cells are injected with an inducer to influence the course of differentiation of the stem cells.
  • FIG. 2 is a drawing of an artificial culture vessel for maintaining mammalian pluripotent stem cells and derivative cells in the presence of components of a telolecithal or eutelolecithal egg.
  • FIG. 3 is a drawing of the various anatomical structures of the fertilized chicken egg, showing the location of the chorioallantoic membrane (CAM) and the placement of mammalian pluripotent stem cells and inducer in juxtaposition to the CAM membrane.
  • CAM chorioallantoic membrane
  • FIG. 4 is a drawing showing the result of placement of mammalian ES cells or embryo-derived cells within the vitelline membrane of an embryonated egg such that the growing teratoma is vascularized by the chick's vitelline vascular plexus.
  • FIG. 5 shows an hematoxylin-and-eosin stained tissue section from a human teratoma formed by the placement of human ES cells within the vitelline membrane of an embryonated egg.
  • FIG. 6 shows the use of SPF chick embryo fibroblasts to stably maintain hES cell lines in an undifferentiated state.
  • B C—colonies of the hES cell line H1 grown on CEF (B) vs. on MEF (C); D-I, hES cell line H7 cultured on CEF (4 passages): D, Oct-4; E, SSEA-3; F, SSEA-4; G, alkaline phosphatase; H, TRA-1-60; I, TRA-1-81.
  • ES Cell Embryonic stem cells derived from a morula or blastocyst-staged mammalian embryo produced by the fusion of a sperm and egg cell, nuclear transfer, parthenogenesis, or the reprogramming of chromatin and subsequent incorporation of the reprogrammed chromatin into a plasma membrane to produce a cell.
  • hEDC Human Embryo-Derived Cells
  • hES Cell Human embryonic stem cells
  • ICM Inner Cell Mass of the blastocyst embryo.
  • the present invention provides methods for the culture of mammalian stem cells, differentiated progeny cells, tissues and organs, and non-human mammalian embryos and fetuses in a telolecithal or eutelolecithal egg such as that of avian or egg laying mammalian species (in ovo).
  • a telolecithal or eutelolecithal egg such as that of avian or egg laying mammalian species
  • the term “in ovo” refers to residence within a shelled telolecithal or eutelolecithal egg, or in the presence of the components of such an egg or eggs cultured in a container other than an egg shell, such container being composed of polymers, glass, or metal.
  • the telolecithal or eutelolecithal eggs useful in the present invention may be from the common domestic chicken ( Gallus gallus domesticus) or from any other avian species including but not limited to the turkey (Meleagris), quail (Cotumix), and duck (Anas) or an egg-laying mammals such as those of the Order Monotremata.
  • the avian eggs useful in this invention for the production of therapeutic products include specific pathogen-free (SPF) eggs.
  • SPF pathogen-free
  • specific pathogen-free refers to eggs that have been obtained from animals reared in conditions to insure that the animals and their eggs are free of known pathogens including avian pathogenic viruses.
  • suicide gene refers to genes that may be introduced into the mammalian stem cells or into the avian inducer cells or into the avian system providing vascular support, such that upon stimulation, the cells that carry the suicide gene can be induced to die.
  • suicide genes are well known in the art and include the use of herpes simplex virus thymidine kinase that in the presence of gancyclovir can cause the death of the cell carrying the gene.
  • mitotically inactivated refers to cells that have been rendered incapable of subsequent cell division by the exposure of such cells to agents that damage the DNA of such cells such that the cells undergo DNA damage checkpoint arrest or apoptosis. Such mitotic inactivation can be achieved by techniques well known in the art such as the use of exogenous radiation, or chemical agents including mitomycin C.
  • teratoma refers to a benign mass of cells differentiating from pluripotent stem cells that organize into complex tissues in three dimensions, though lacking the normal and intact form of an animal and incapable of independent life.
  • teratomas have been reported to occur following the injection of hES cells into the skeletal muscle or peritoneum of immunocompromised mice where such teratomas contain intenstine, skin, teeth, renal tissue, neuronal tissue, bone, cartilage, and so on.
  • CAM chorioallantoic membrane
  • pluripotent stem cells refers to animal cells capable of differentiating into more than one differentiated cell type. Such cells include hES cells, hEDCs, and adult-derived cells including mesenchymal stem cells, neuronal stem cells, and bone marrow-derived stem cells. Pluripotent stem cells may be genetically modified or not genetically modified. Genetically modified cells may include markers such as fluorescent proteins to facilitate their identification within the egg.
  • ES cells refers to cells derived from the inner cell mass of blastocysts or morulae that have been serially passaged as cell lines.
  • the ES cells may be derived from fertilization of an egg cell with sperm or DNA, nuclear transfer, parthenogenesis, or by means to generate hES cells with homozygosity in the MHC region.
  • human embryonic stem cells hES cells
  • hES cells refers to cells derived from the inner cell mass of human blastocysts or morulae that have been serially passaged as cell lines.
  • the hES cells may be derived from fertilization of an egg cell with sperm or DNA, nuclear transfer, parthenogenesis, or by means to generate hES cells with homozygosity in the HLA region.
  • hEDC human embryo-derived cells
  • the term “human embryo-derived cells” refer to morula-derived cells, blastocyst-derived cells including those of the inner cell mass, embryonic shield, or epiblast, or other totipotent or pluripotent stem cells of the early embryo, including primitive endoderm, ectoderm, and mesoderm and their derivatives, but excluding hES cells that have been passaged as cell lines.
  • the hEDC cells may be derived from fertilization of an egg cell with sperm or DNA, nuclear transfer, parthenogenesis, or by means to generate hES cells with homozygosity in the HLA region.
  • mammalian pluripotent stem cells with or without inducer molecules or cells are injected within and in juxtaposition to the vitelline membranes of the unembryonated egg ( FIG. 1 ).
  • One mammalian pluripotent cell, or a plurality of cells, for example, a colony of cultured mammalian pluripotent stem cells such as ES cells, in particular hES or hEDC cells can be injected by techniques well known in the art, such as incubating an egg at 37-39° C. in 60% humidity, the shell cleaned with 70% ethanol, and using a sterile syringe, approximately 2.5 mL of albumin will be removed.
  • the egg may be injected at one site, or multiple sites, including at or near the blastodisc, depending on the nature of the cells and the type of product desired.
  • the cells with or without inducer may be injected within the vitelline membrane but external to the developing embryo of an embryonated egg such that the differentiated cells are vascularized by the vitelline vascular plexus.
  • the differentiated cells can then be removed from the egg and purified from the yolk sac prior to hatching.
  • the chicken can be allowed to develop to hatching, in which case the yolk sac membrane is absorbed within the body cavity of the chick and the mammalian teratoma continues to develop within the body of the hatched chick and the differentiated mammalian cells can be removed post hatch.
  • the advantages of obtaining the cells post hatch are that it allows more time for greater growth and development of the teratoma and it provides early exposure of the chick to the mammalian pluripotent stem cells which tolerizes the immune system and lessens chances of rejection.
  • the injection of the cells into embryonated eggs is by techniques well known in the art for the injection of cells, such as the injection of avian blastodermal cells into the blastoderm of a fertilized egg to generate chimeras.
  • the egg is cultured at 37° C. or in the proximity to the normal temperature for human cells (i.e.
  • the components of the egg will be transferred to a container such as that shown in FIG. 2 to replace the function of the egg shell and to facilitate the manipulation of the culture system.
  • a container such as that shown in FIG. 2 to replace the function of the egg shell and to facilitate the manipulation of the culture system.
  • Such container may contain a transparent component to allow the viewing of the developing tissue, ports for the removal, replacement, or addition of egg components such as egg albumin or a culture medium or matrix substrate substituting for albumin, egg yolk, mammalian pluripotent stem cells including hES or hEDC, or inducer molecules or cells, the cannulation of blood vessels within the differentiating tissue for external circulatory or respiratory support, or a system such as a semipermeable membrane to facilitate the diffusion of gases and small molecules into and out of the culture system.
  • an artificial container also allows for the introduction of egg components from multiple eggs for culture of cells of animals of long gestational age and where larger tissues or larger extraembryonic membranes are desired, with or without supplemental calcium and ascorbate to approximate the physiological levels of the corresponding mammalian species.
  • mammalian pluripotent stem cells including hES and hEDC cells are injected in the proximity of the shell membrane to form a teratoma that will subsequently become vascularized by the growing CAM membrane ( FIG. 3 ).
  • the egg will be incubated at approximately 37° C. and 60% humidity, the shell cleaned with 70% ethanol, and using a sterile syringe, approximately 2.5 mL of albumin will be removed. This allows a small, typically 1.5 cm 2 window to be cut in the shell and the shell membrane allowing the mammalian pluripotent cells to be injected within the albumin and in juxtaposition to the shell membrane.
  • the mammalian pluripotent cells may be injected between day 1 and day 17.
  • the teratoma may subsequently be removed and cultured in organ culture with the attached vasculature used to perfuse the growing tissue with blood or tissue culture media. Any residual avian cells may be removed by activation of the avian suicide genes.
  • mammalian pluripotent stem cells including hES and hEDC are injected by the above techniques in the amniotic cavity, albumin, air space, allantoic cavity, extraembryonic coelom, or the yolk sac of the egg and allowed to differentiate over time in the incubated egg.
  • the inducer includes cells that are derived from cells of a heterologous species, such as chicken somatic cells inducing the differentiation of hES cells.
  • a heterologous species such as chicken somatic cells inducing the differentiation of hES cells.
  • Such cells can be cells that normally occur in juxtaposition to the cell of interest and include stromal cells and endothelial cells from the organ or parenchyma of interest.
  • the somatic inducer cells can be obtained from a variety genotypes including SPF eggs to reduce the risk of pathogen transmission.
  • Such eggs are commercially available (Charles River Laboratories) and are free of such pathogens as Avian Adenovirouses I-III, Avian Encephalomyelitis, Avian Influenza (Type A), Avian Nephritis Virus, Avian Paramyxovirus Type 2, Avian Reovirus, Avian Rhinotracheitis Virus, Avian Rotavirus, Avian Tuberculosis, Chicken Anemia Virus, Endogenous GS Antigen, Fowl Pox, Hemophilus paragallinarum , Infectious Bronchitis (Ark, Conn, JMK, and Mass), Infectious Bursal Disease, Infectious Laryngotracheitis, Lymphoid Leukosis A,B, Lymphoid Leukosis Viiruses, Marek's Disease (Serotypes 1,2,3), Mycoplasma gallisepticum, Mycoplasma synoviae , Newcastle Disease, Reticuloendotheliosis Virus,
  • the inducer cells are derived from ES cells of a heterologous species.
  • the inducer cells may be cES cells differentiated into somatic cells that function in inducing the specific differentiation of hES cells.
  • the cES cells can be obtained from a variety genotypes including SPF eggs to reduce the risk of pathogen transmission.
  • the cES cells can be cultured indefinitely in an undifferentiated state, they can be genetically modified using techniques well known in the art for improved performance as inducer cells.
  • Such genetic modifications include the introduction of suicide genes that allow the destruction of the inducer cells prior to use, modified to express cell surface antigens that facilitate the removal of the inducer cells by affinity methods well known in the art, or the inducer ES cells may be modified by gene trap vectors in order to obtain ES cell clones that express markers such as fluorescent proteins that facilitate the purification and identification of particular differentiated cell types as inducer cell lines.
  • the inducer is one of a number of extracellular signaling molecules including growth factors, cytokines, extracellular matrix components, nucleic acids encoding the foregoing, steroids, and morphogens or neutralizing antibodies to such factors.
  • Such inducers include but are not limited to: cytokines such as interleukin-alpha A, interferon-alpha A/D, interferon-beta, interferon-gamma, interferon-gamma-inducible protein-10, interleukin-1-17, keratinocyte growth factor, leptin, leukemia inhibitory factor, macrophage colony-stimulating factor, and macrophage inflammatory protein-1 alpha, 1-beta, 2, 3 alpha, 3 beta, and monocyte chemotactic protein 1-3.
  • Differentiation agents according to the invention also include growth factors such as 6kine, activin A, amphiregulin, angiogenin, ⁇ -endothelial cell growth factor, ⁇ -cellulin, brain-derived neurotrophic factor, C10, cardiotrophin-1, ciliary neurotrophic factor, cytokine-induced neutrophil chemoattractant-1, eotaxin, epidermal growth factor, epithelial neutrophil activating peptide-78, erythropioetin, estrogen receptor-alpha, estrogen receptor-beta, fibroblast growth factor (acidic and basic), heparin, FLT-3/FLK-2 ligand, glial cell line-derived neurotrophic factor, Gly-His-Lys, granulocyte colony stimulating factor, granulocytomacrophage colony stimulating factor, GRO- ⁇ /MGSA, GRO- ⁇ , GRO-gamma, HCC-1, heparin-binding epidermal growth factor, hepat
  • Differentiation agents according to the invention also include hormones and hormone antagonists such as 17B-estradiol, adrenocorticotropic hormone, adrenomedullin, alpha-melanocyte stimulating hormone, chorionic gonadotropin, corticosteroid-binding globulin, corticosterone, dexamethasone, estriol, follicle stimulating hormone, gastrin 1, glucagons, gonadotropin, L-3,3′,5′-triiodothyronine, leutinizing hormone, L-thyroxine, melatonin, MZ-4, oxytocin, parathyroid hormone, PEC-60, pituitary growth hormone, progesterone, prolactin, secretin, sex hormone binding globulin, thyroid stimulating hormone, thyrotropin releasing factor, thyroxin-binding globulin, and vasopressin.
  • hormones and hormone antagonists such as 17B-estradio
  • differentiation agents according to the invention include extracellular matrix components such as fibronectin, proteolytic fragments of fibronectin, laminin, tenascin, thrombospondin, and proteoglycans such as aggrecan, heparan sulphate proteoglycan, chontroitin sulphate proteoglycan, and syndecan.
  • extracellular matrix components such as fibronectin, proteolytic fragments of fibronectin, laminin, tenascin, thrombospondin, and proteoglycans such as aggrecan, heparan sulphate proteoglycan, chontroitin sulphate proteoglycan, and syndecan.
  • extracellular matrix components such as fibronectin, proteolytic fragments of fibronectin, laminin, tenascin, thrombospondin, and proteoglycans such as aggrecan, heparan sulphate proteogly
  • Differentiation agents according to the invention also include antibodies to the previously-mentioned cytokines, growth factors, hormones, and extracellular matrix components, and their receptors.
  • the present invention also provides for a means of developing human extra-embryonic membranes that can function to support the near normal differentiation of cells from hES cells or hED cells in ovo.
  • the injection of such human pluripotent stem cells such as hES cells at or near the vitelline membrane of either an embryonated or unembryonated egg results in the differentiation of some of the injected cells into extra-embryonic membranes such as human amnion, chorion, and yolk sac, that in turn provide laboratory models of cell differentiation, and the derivation of yolk sac hematopoietic precursor cells, and extra-embryonic membranes useful in supporting the growth and differentiation of such stem cells.
  • the present invention also provides for a means of developing mammalian extra-embryonic membranes that can function to support the near normal development of non-human fetuses.
  • mammalian extra-embryonic membranes that can function to support the near normal development of non-human fetuses.
  • such species as the domestic pig display extra-embryonic membrane formation closely resembling that of avian species and such animals can be gestated within the avian egg or within an artificial device such as that shown in FIG. 2 .
  • the inner cell mass or embryonic disc or embryonic stem cells of such non-human mammalian preimplantation embryo or peri-implantation embryo can be grafted into or near the blastodisc of an unfertilized avian egg, or the blastoderm of a fertilized avian egg can be removed or inactivated and replaced by the intact ICM or embryonic disc of a non-human mammalian embryo with or without supplemental calcium and ascorbate to approximate the physiological levels of the corresponding mammalian species
  • the present invention also provides a means of influencing the differentiated state of cultured hES cells, hED cells, and cells differentiated from such cells by co-culturing such cells with SPF avian differentiated cells.
  • SPF avian chick embryo fibroblasts including but not limited to chick embryo fibroblasts from SPF embryonated eggs at nine days of culture may be isolated by techniques well known in the art such as by removing such nine day-old chick embryos, disaggregating the tissues, and plating the cells in standard fibroblast growth conditions such as MEM medium supplemented with 10% FBS or defined pathogen-free medium.
  • hES cells may then be serially passaged on mitotically-inactivated SPF chick embryo fibroblasts instead of using feeder cells such as murine embryo fibroblasts with an uncharacterized pathogen status.
  • the co-culture of hES cells with SPF chick embryo fibroblasts has a clear utility in facilitating the scale up of hES cells in pathogen-free culture conditions.
  • the use of other specific SPF chick cells may similarly be used where such cells are known to cause the induction of differentiation in order to influence the differentiation of hES, hED cells, or other downstream pluripotent human cells.
  • Examples of cell types that function as inducers of differentiation are well known in the art and include mesodermal cells such as the stromal cells from the aorta-gonadal-mesonephros region which induce definitive hematopoiesis in pluripotent stem cells, ectodermal cells such as the optic vesicle cells, or mesenchymal cells from the optic vesicle that induce the differentiation of ectodermal cells into lens cells, and endodermal cells such as the induction of pancreatic islet cells, including pancreatic beta cells from primitive endodermal epithelium by pancreatic mesenchymal cells.
  • mesodermal cells such as the stromal cells from the aorta-gonadal-mesonephros region which induce definitive hematopoiesis in pluripotent stem cells
  • ectodermal cells such as the optic vesicle cells, or mesenchymal cells from the optic vesicle that induce the differentiation of ectodermal
  • Induction can also occur by epithelio-stromal interactions and by the use of one germ-layer to induce cells of another germ-layer, such as the use of dermal mesoderm cells to induce epidermal differentiation such as hair differentiation, mesodermally-derived cells that induce gut and ultimately pancreatic islet cell differentiation, the mesodermal cells of the ureteric bud that induce kidney differentiation, the mesodermal induction of epithelium to produce pharyngeal thymus and thyroid differentiation, liver mesenchymal cells that induce primitive epithelium to differentiate into hepatic cords and liver parenchyma, gut mesenchymal cells that induce primitive epithelial cells to differentiate into gut, tracheal mesenchymal cells that induce respiratory differentiation such as respiratory epithelium,
  • Such inducer cells can be removed from the corresponding region of an SPF chick embryo by standard dissection, or isolated from SPF chick ES cell lines utilizing genetic markers for that lineage of cells, such as exogenous markers with exogenous
  • the present invention also provides a means of reconstituting mammalian cells from chromatin, by removing or inactivating the avian DNA from the blastodisc of an avian embryo using techniques well known in the art, and replacing said genome with the haploid or preferably the diploid genome of a mammalian cell.
  • the mammalian cell genome may be by way of example, human somatic cell-derived chromatin that has been reprogrammed and condensed by exposure in vitro to extracts or purified components from metaphase II oocytes as is known in the art. Subsequent or at about the time of the transfer of chromatin, the oocyte is activated such that there is an elevation of intracellular calcium.
  • this invention provides a novel method of activating the oocyte of a telolecithal or eutelolecithal egg in conjunction with the transfer of chromatin from a mammalian species, said method being the injection and subsequent removal of a sperm, multiple sperm, or sperm heads, and their subsequent removal.
  • chromatin transfer and activation rounds of karyokinesis and cytokinesis that follow result in cells similar in nature to hES or hEDC cells on the in juxtaposition to the vitelline membrane as previously described.
  • the disclosed methods for the culture of animal tissues are generally useful in mammalian subjects, including human and non-human subjects, and particularly in the culture of non-human embryos and fetuses and for the culture and differentiation of mammalian pluripotent stem cells, in particular, hES cells and hEDC.
  • telolecithal eggs such as avian eggs
  • the methods of the present invention can be used for culturing non-human embryos such as pigs to advanced stages of development, and for the manufacture of animal cells, such as human cells useful in drug discovery, basic research, and in cell therapy.
  • hES cells and other mammalian ES cells are cultured and differentiated within the avian egg.
  • avian egg refers to the fertilized or unfertilized egg of an avian species including but not limited to eggs of the domestic chicken ( Gallus domesticus), the turkey, duck, ostrich, and quail.
  • complex tissues can be produced using this invention, similar to the production of teratomas which are disorganized aggregations of human tissue that form after the injection of human embryonic stem cells into immunocompromised mice.
  • the resultant differentiated progenitor cells or fully differentiated cells of the present invention have numerous therapeutic and diagnostic, and basic research applications. Most specifically, such differentiated cells may be used for cell transplantation therapies. Human differentiated cells have application in the treatment of numerous disease conditions.
  • the subject differentiated cells may be used to obtain any desired differentiated cell type. Therapeutic useages of such differentiated cells are unparalleled.
  • human hematopoietic stem cells and hemangioblasts may be used to treat many diseases that compromise the immune system, such as AIDS, cancer therapy, or age-related immune dysfunction.
  • Hematopoietic stem cells can be obtained, e.g., by fusing adult somatic cells of a cancer or AIDS patient, e.g., fibroblasts or blood cells with an enucleated oocyte, obtaining inner cell mass cells, and culturing such cells in ovo under conditions which favor differentiation until hematopoietic stem cells or hemangioblasts are obtained.
  • hES or hEDC cells or primitive mesodermal cells derived from such cells can be injected in ovo using one of the techniques described herein in conjunction with stromal fibroblasts from the aorta-gonadal-mesonephros region of a non-human mammalian embryo or fetus or avian species to induce the differentiation of the cells into hemangioblasts and hematopoietic stem cells.
  • Such cells may then be used with or without genetic modification for the treatment of diseases including AIDS, cancer, and immune dysfunction.
  • the cells can also be used in veterinary practice to treat canine or feline disease using cell therapy.
  • adult somatic cells from a patient with a neurological disorder may be fused with an enucleated oocyte, human inner cell mass cells obtained therefrom, and such cells cultured in ovo under differentiation conditions to produce neural cell lines and neural progenitor cells lines.
  • Specific diseases treatable by transplantation of such human neural cells include, by way of example, Parkinson's disease, Alzheimer's disease, ALS, palsy, and spinal cord injury among others.
  • Parkinson's disease it has been demonstrated that transplanted fetal brain neural cells make the proper synapses with surrounding cells and produce dopamine. This can result in long-term reversal of Parkinson's disease symptoms and disease progression.
  • the great advantage of the subject invention is that it provides an essentially limitless supply of isogenic or homozygous MHC cells suitable for transplantation. Therefore, it will obviate the significant problem associated with current transplantation methods, i.e., rejection of the transplanted tissue which may occur because of host-vs-graft or graft-vs-host rejection. Conventionally, rejection is prevented or reduced by the administration or anti-rejection drugs such as cyclosponine. However, such drugs have significant adverse side-effects, e.g., immunosuppression, carcinogenic properties, as well as being costly.
  • the present invention will eliminate, or in the case of homozygous MHC cells, greatly reduce the need for anti-rejection drugs.
  • the present invention provides a means of directly differentiating cells in the context of a SPF culture system capable of generating complex tissues. It also allows for the introduction of inducer molecules and cells from similar or identical SPF species to direct the differentiation of the cells without the complication of pathogen transmission from murine or other retroviruses or other unknown agents.
  • the present invention provides methods to culture mammalian teratomas near the CAM of an embryonated telolecithal or eutelolecithal egg such that the teratoma is provided vascular support from the developing chick. Such a teratoma can be later removed from the egg and cannulated to provide a growing and vascularized three-dimensional tissue.
  • the ability to assemble three dimensional aggregates of cells derived from such cells as hES and hEDC cells with vasculature is an important and novel advance facilitating the production of such tissues as renal tissue, heart tissue, liver tissue, pancreatic tissue, lung, as well as many other tissue types with dimensions in excess of 0.5 mm in diameter.
  • non-human mammalian embryos and fetuses are gestated in ovo.
  • This system would have great utility in producing cloned offspring where the relative inefficiencies and high cost of recipient animals leads to a high end cost of product.
  • Animals such as domestic pigs whose extraembryonic membranes closely resemble that of the avian embryo and whose placenta does not form a syncitia with the maternal uterus are especially suited for development in ovo.
  • genetically modified non-human animals developed in ovo provide a sterile and SPF system for producing cells and tissues for xenotransplantation.
  • the non-human animal developing in ovo can be used as an intact animal to induce the differentiation of mammalian pluripotent stem cells including hES and hEDC cells.
  • hES or hEDC cells or primitive mesodermal cells derived from such cells can be injected into the aorta-gonadal-mesonephros region of a non-human mammalian embryo or fetus to induce the differentiation of the cells into hemangioblasts and hematopoietic stem cells.
  • the high value placed on mature human oocytes will lead to improved technologies to remodel the chromatin of human cells in oocyte extracts, or eventually to reprogram human DNA using defined molecular components.
  • Such technology is currently known in the art where the extract is obtained from metaphase II oocytes.
  • the reprogrammed chromatin resulting from such reprogramming can be injected into the blastodisc of an unfertilized telolecithal or eutelolecithal egg with resulting rounds of karyokinesis and cytokinesis resulting in reconstituted and reprogrammed cells within the vitelline membrane.
  • Such cellular reconstitution especially where such cells can be subsequently grown and differentiated in ovo as described in the present invention, provides an efficient and cost-effective means of producing differentiated cells of many kinds under SPF conditions and would therefore have great utility and value in producing human and non-human animal cells for basic research, drug discovery, and cell therapy.
  • pluripotent stem cells such as hES cells into desired differentiated cell types such as definitive hemangioblasts, pancreatic islet cells, heart muscle precursor cells, neural progenitor cells, renal cells, liver cells, lung cells, cartilage cells, or dermal cells demonstrates the need for new technologies to direct the differentiation of such pluripotent cells and to grow the cells in a defined pathogen-free culture system.
  • the present invention provides a novel mean of expanding hES cells in vitro with feeder cells that, unlike murine embryo fibroblasts, are known to be pathogen free, thereby allowing the hES cells to be cultured in conditions that assure their being free of exogenous pathogens and therefore minimizing the risk of transmitting pathogens to patients in need of such cell therapy.
  • CEF were isolated from 7-8 day old chicken embryos with the heads left on, using the previously described techniques for isolation of mouse embryonic fibroblasts. Briefly, the embryos were eviscerated, the heads left on, digested with trypsin and plated onto gelatin coated plates in DMEM, supplemented with 10% FBS, glutamine and penicillin-streptomycin. The cells were frozen at passage one and used at passage 2 after mitotic inactivation with mitomycin C.
  • H9, H7 both NIH-approved
  • ACT-4 derived here from passage 9-11 and 15-19.
  • FIG. 6 shows the undifferentiated hES grown on the CEF.
  • a cloned or normal porcine blastocyst with or without a transgenic suicide gene is held with an aspiration pipette under low magnification and the trophectoderm is torn opposite the inner cell mass to yield near-planar aggregation of cells.
  • the torn blastocyst is injected with a 200 micron pipette into an unfertilized but fresh SPF windowed avian egg at or near the blastodisc.
  • the resulting reconstructed egg is then resealed with kitchen wrap as is well known in the art and cultured at 37° C. on a racking platform.
  • hES or hED cells are injected into the porcine embryo.
  • the human pluripotent stem cells are injected into the aortic-gonadal-mesonephros region of the porcine embryo to induce differentiation into hematopoietic differentiation such as hemangioblasts.
  • hES or hED cells are co-cultured with mesenchymal cells dissected from the aortic-gonadal-mesonephros region of SPF avian embryos to induce differentiation into hematopoietic differentiation such as hemangioblasts.
  • the co-culture is incubated in pathogen-free tissue culture until primitive hemangioblasts are produced which are subsequently purified by the use of antigens such as CD4, AC133, c-kit, or other antigens well known in the art.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
US11/028,345 2004-01-02 2005-01-03 Novel culture systems for ex vivo development Abandoned US20060112438A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US11/028,345 US20060112438A1 (en) 2004-01-02 2005-01-03 Novel culture systems for ex vivo development
US11/211,174 US7910369B2 (en) 2004-01-02 2005-08-24 Culture systems for ex vivo development

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53444704P 2004-01-02 2004-01-02
US53979604P 2004-01-28 2004-01-28
US11/028,345 US20060112438A1 (en) 2004-01-02 2005-01-03 Novel culture systems for ex vivo development

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/211,174 Continuation US7910369B2 (en) 2004-01-02 2005-08-24 Culture systems for ex vivo development

Publications (1)

Publication Number Publication Date
US20060112438A1 true US20060112438A1 (en) 2006-05-25

Family

ID=34798830

Family Applications (5)

Application Number Title Priority Date Filing Date
US11/028,345 Abandoned US20060112438A1 (en) 2004-01-02 2005-01-03 Novel culture systems for ex vivo development
US11/211,174 Active 2026-10-12 US7910369B2 (en) 2004-01-02 2005-08-24 Culture systems for ex vivo development
US11/478,780 Abandoned US20070067860A1 (en) 2004-01-02 2006-06-29 Novel culture systems for ex vivo development
US13/172,027 Active US8597944B2 (en) 2004-01-02 2011-06-29 Culture systems for ex vivo development
US14/066,510 Abandoned US20140057348A1 (en) 2004-01-02 2013-10-29 Novel Culture System for Ex Vivo Development

Family Applications After (4)

Application Number Title Priority Date Filing Date
US11/211,174 Active 2026-10-12 US7910369B2 (en) 2004-01-02 2005-08-24 Culture systems for ex vivo development
US11/478,780 Abandoned US20070067860A1 (en) 2004-01-02 2006-06-29 Novel culture systems for ex vivo development
US13/172,027 Active US8597944B2 (en) 2004-01-02 2011-06-29 Culture systems for ex vivo development
US14/066,510 Abandoned US20140057348A1 (en) 2004-01-02 2013-10-29 Novel Culture System for Ex Vivo Development

Country Status (7)

Country Link
US (5) US20060112438A1 (fr)
EP (1) EP1711594A4 (fr)
AU (1) AU2005205516B2 (fr)
CA (2) CA2852122A1 (fr)
IL (1) IL176641A (fr)
NZ (1) NZ548623A (fr)
WO (1) WO2005068610A1 (fr)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070026516A1 (en) * 2005-07-26 2007-02-01 Martin Gregory R Multilayered cell culture apparatus
US20080003671A1 (en) * 2006-06-30 2008-01-03 Gregory Roger Martin Fluid flow diverter for cell culture vessel
WO2008028124A1 (fr) * 2006-09-01 2008-03-06 The Board Of Trustees Of The University Of Arkansas Procédés et systèmes de détection de contaminants
US20080206791A1 (en) * 2005-01-07 2008-08-28 Board Of Trustees Of The University Of Arkansas Method for detecting an unknown contaminant concentration in a substance
US20080206857A1 (en) * 2007-02-26 2008-08-28 Kenney David A Device and method for reducing bubble formation in cell culture
US20080299649A1 (en) * 2007-05-29 2008-12-04 Martin Gregory R Cell culture apparatus for co-culture of cells
US8257964B2 (en) 2006-01-04 2012-09-04 Cell ASIC Microwell cell-culture device and fabrication method
US9206384B2 (en) 2011-12-03 2015-12-08 Emd Millipore Corporation Micro-incubation systems for microfluidic cell culture and methods
US9260688B2 (en) 2005-07-07 2016-02-16 The Regents Of The University Of California Methods and apparatus for cell culture array
US9354156B2 (en) 2007-02-08 2016-05-31 Emd Millipore Corporation Microfluidic particle analysis method, device and system
US9353342B2 (en) 2010-01-21 2016-05-31 Emd Millipore Corporation Cell culture and gradient migration assay methods and devices
US9376658B2 (en) 2008-01-03 2016-06-28 Emd Millipore Corporation Cell culture array system for automated assays and methods of operation and manufacture thereof
US9388374B2 (en) 2005-07-07 2016-07-12 Emd Millipore Corporation Microfluidic cell culture systems
US9637715B2 (en) 2005-07-07 2017-05-02 Emd Millipore Corporation Cell culture and invasion assay method and system
US10526572B2 (en) 2011-04-01 2020-01-07 EMD Millipore Corporaticn Cell culture and invasion assay method and system
US11422125B2 (en) 2015-03-23 2022-08-23 Astellas Institute For Regenerative Medicine Assays for potency of human retinal pigment epithelium (RPE) cells and photoreceptor progenitors
WO2024057159A1 (fr) * 2022-09-14 2024-03-21 Politecnico Di Milano Système accessible optiquement pour études sur œufs embryonnés

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004025086B4 (de) * 2004-05-21 2007-10-18 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren und Vorrichtung zum Kultivieren von Stammzellen
EP1878789A4 (fr) * 2005-04-14 2008-08-27 Japan As Represented By Genera Cellule souche dérivée de graisse et son utilisation
US20060286666A1 (en) * 2005-06-17 2006-12-21 Kang Ji Y Methods and apparatuses for culturing stem cell using biomaterial shell
US7536739B2 (en) * 2005-08-10 2009-05-26 Kreg Medical, Inc. Therapeutic mattress
US20080064098A1 (en) * 2006-06-05 2008-03-13 Cryo-Cell International, Inc. Procurement, isolation and cryopreservation of maternal placental cells
US20080050814A1 (en) * 2006-06-05 2008-02-28 Cryo-Cell International, Inc. Procurement, isolation and cryopreservation of fetal placental cells
JP2013531987A (ja) * 2010-06-14 2013-08-15 キアゲン ゲーエムベーハー 固定生物学的試料から生体分子を抽出するためのターゲット細胞または組織を決定するための方法
ES2963295T3 (es) 2010-07-12 2024-03-26 Univ Southern California Sustrato biocompatible para facilitar las interconexiones entre células madre y tejidos diana y métodos para implantarlo
WO2012007502A1 (fr) * 2010-07-14 2012-01-19 Qiagen Gmbh Dispositif d'isolement et/ou de purification de biomolécules
EP2593768A1 (fr) 2010-07-14 2013-05-22 Qiagen GmbH Nouveau dispositif de stockage, de collecte ou d'isolement
US8877489B2 (en) 2011-12-05 2014-11-04 California Institute Of Technology Ultrathin parylene-C semipermeable membranes for biomedical applications
WO2012149468A2 (fr) 2011-04-29 2012-11-01 University Of Southern California Instruments et procédés d'implantation de substrats ensemencés de cellules
WO2013010045A1 (fr) 2011-07-12 2013-01-17 Biotime Inc. Nouveaux procédés et formulations pour thérapie cellulaire orthopédique
DK2785359T3 (en) 2011-11-30 2018-10-29 Astellas Inst For Regenerative Medicine MESENKYMAL STROMACELLES AND APPLICATIONS RELATED
US9248013B2 (en) 2011-12-05 2016-02-02 California Institute Of Technology 3-Dimensional parylene scaffold cage
US20140178988A1 (en) 2012-10-08 2014-06-26 Biotime, Inc. Differentiated Progeny of Clonal Progenitor Cell Lines
US20140255447A1 (en) * 2013-03-05 2014-09-11 Biomune Company Production of avian embryo cells
CA2914615C (fr) 2013-06-05 2023-10-17 Biotime, Inc. Compositions et procedes pour la regeneration de tissus induite chez des especes mammaliennes
US11078462B2 (en) 2014-02-18 2021-08-03 ReCyte Therapeutics, Inc. Perivascular stromal cells from primate pluripotent stem cells
JP6580329B2 (ja) 2014-03-31 2019-09-25 シスメックス株式会社 未分化細胞から分化細胞および／または分化細胞の産生物を取得する方法
US10240127B2 (en) 2014-07-03 2019-03-26 ReCyte Therapeutics, Inc. Exosomes from clonal progenitor cells
RU2644650C2 (ru) 2014-12-01 2018-02-13 Общество с ограниченной ответственностью "Т-Хелпер Клеточные Технологии" Материал стволовых клеток и способ его получения
US10384207B2 (en) 2015-07-21 2019-08-20 Neuro Probe Incorporated Assay apparatus and methods
CA3202332A1 (fr) 2015-12-07 2017-06-15 Agex Therapeutics, Inc. Procedes de re-derivation de diverses cellules de tissu adipeux brun derivees de cellules souches pluripotentes
RU2708329C2 (ru) 2016-05-31 2019-12-05 Общество с ограниченной ответственностью "Т-Хелпер Клеточные Технологии" Материал стволовых клеток, композиции и способы применения

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5340740A (en) * 1992-05-15 1994-08-23 North Carolina State University Method of producing an avian embryonic stem cell culture and the avian embryonic stem cell culture produced by the process

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5480772A (en) * 1993-02-03 1996-01-02 Brandeis University In vitro activation of a nucleus
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US20020194637A1 (en) * 2001-06-06 2002-12-19 University Of Massachussetts Embryonic or stem-like cell lines produced by cross species nuclear transplantation
US7410798B2 (en) 2001-01-10 2008-08-12 Geron Corporation Culture system for rapid expansion of human embryonic stem cells
WO2003048344A2 (fr) * 2001-12-07 2003-06-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Differenciation de cellules souches embryonnaires humaines dans des embryons aviaires
GB0129811D0 (en) * 2001-12-13 2002-01-30 Viragen Inc Enucleation in avian cells

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5340740A (en) * 1992-05-15 1994-08-23 North Carolina State University Method of producing an avian embryonic stem cell culture and the avian embryonic stem cell culture produced by the process

Cited By (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080206791A1 (en) * 2005-01-07 2008-08-28 Board Of Trustees Of The University Of Arkansas Method for detecting an unknown contaminant concentration in a substance
US7939343B2 (en) 2005-01-07 2011-05-10 Board Of Trustees Of The University Of Arkansas Method for detecting an unknown contaminant concentration in a substance
US10190085B2 (en) 2005-07-07 2019-01-29 Emd Millipore Corporation Micro-incubation systems for microfluidic cell culture and methods
US9969963B2 (en) 2005-07-07 2018-05-15 The Regents Of The University Of California Methods and apparatus for cell culture array
US10843189B2 (en) 2005-07-07 2020-11-24 The Regents Of The University Of California Methods and apparatus for cell culture array
US9260688B2 (en) 2005-07-07 2016-02-16 The Regents Of The University Of California Methods and apparatus for cell culture array
US9388374B2 (en) 2005-07-07 2016-07-12 Emd Millipore Corporation Microfluidic cell culture systems
US9637715B2 (en) 2005-07-07 2017-05-02 Emd Millipore Corporation Cell culture and invasion assay method and system
US10138453B2 (en) 2005-07-07 2018-11-27 Emd Millipore Corporation Cell culture array system for automated assays and methods of operation and manufacture
US7745209B2 (en) 2005-07-26 2010-06-29 Corning Incorporated Multilayered cell culture apparatus
US11905506B2 (en) 2005-07-26 2024-02-20 Corning Incorporated Multilayered cell culture apparatus
US9845451B2 (en) 2005-07-26 2017-12-19 Corning Incorporated Multilayered cell culture apparatus
US8273572B2 (en) 2005-07-26 2012-09-25 Corning Incorporated Methods of using multilayered cell culture apparatus
US8470589B2 (en) 2005-07-26 2013-06-25 Corning Incorporated Multilayered cell culture apparatus
US11274273B2 (en) 2005-07-26 2022-03-15 Corning Incorporated Multilayered cell culture apparatus
US20070026516A1 (en) * 2005-07-26 2007-02-01 Martin Gregory R Multilayered cell culture apparatus
US8846399B2 (en) 2005-07-26 2014-09-30 Corning Incorporated Multilayered cell culture apparatus
US9040290B2 (en) 2005-07-26 2015-05-26 Corning Incorporated Multilayered cell culture apparatus
US9045721B2 (en) 2005-07-26 2015-06-02 Corning Incorporated Multilayered cell culture apparatus
US9290730B2 (en) 2005-07-26 2016-03-22 Corning Incorporated Multilayered cell culture apparatus
US10174278B2 (en) 2006-01-04 2019-01-08 Emd Millipore Corporation Valved, microwell cell-culture device and method
US8673625B2 (en) 2006-01-04 2014-03-18 Emd Millipore Corporation Valved, microwell cell-culture device and method
US9371929B2 (en) 2006-01-04 2016-06-21 Emd Millipore Corporation Valved, microwell cell-culture device and method
US8257964B2 (en) 2006-01-04 2012-09-04 Cell ASIC Microwell cell-culture device and fabrication method
US8709790B2 (en) 2006-01-04 2014-04-29 Emd Millipore Corporation Valved, microwell cell-culture device and method
US7745210B2 (en) 2006-06-30 2010-06-29 Corning Incorporated Fluid flow diverter for cell culture vessel
US20080003671A1 (en) * 2006-06-30 2008-01-03 Gregory Roger Martin Fluid flow diverter for cell culture vessel
US20100120016A1 (en) * 2006-09-01 2010-05-13 Yanbin Li Methods and systems for detection of contaminants
WO2008028124A1 (fr) * 2006-09-01 2008-03-06 The Board Of Trustees Of The University Of Arkansas Procédés et systèmes de détection de contaminants
US10054536B2 (en) 2007-02-08 2018-08-21 Emd Millipore Corporation Microfluidic particle analysis method, device and system
US10900886B2 (en) 2007-02-08 2021-01-26 Emd Millipore Corporation Microfluidic particle analysis method, device and system
US9354156B2 (en) 2007-02-08 2016-05-31 Emd Millipore Corporation Microfluidic particle analysis method, device and system
US20080206857A1 (en) * 2007-02-26 2008-08-28 Kenney David A Device and method for reducing bubble formation in cell culture
US7897379B2 (en) 2007-02-26 2011-03-01 Corning Incorporated Device and method for reducing bubble formation in cell culture
US20080299649A1 (en) * 2007-05-29 2008-12-04 Martin Gregory R Cell culture apparatus for co-culture of cells
US10144910B2 (en) 2007-05-29 2018-12-04 Corning Incorporated Cell culture apparatus for co-culture of cells
US9309491B2 (en) 2007-05-29 2016-04-12 Corning Incorporated Cell culture apparatus for co-culture of cells
US9376658B2 (en) 2008-01-03 2016-06-28 Emd Millipore Corporation Cell culture array system for automated assays and methods of operation and manufacture thereof
US10179897B2 (en) 2010-01-21 2019-01-15 Emd Millipore Corporation Cell culture and gradient migration assay methods and devices
US9353343B2 (en) 2010-01-21 2016-05-31 Emd Millipore Corporation Cell culture and gradient migration assay methods and devices
US9353342B2 (en) 2010-01-21 2016-05-31 Emd Millipore Corporation Cell culture and gradient migration assay methods and devices
US10526572B2 (en) 2011-04-01 2020-01-07 EMD Millipore Corporaticn Cell culture and invasion assay method and system
US11034925B2 (en) 2011-04-01 2021-06-15 Emd Millipore Corporation Cell culture and invasion assay method and system
US9428723B2 (en) 2011-12-03 2016-08-30 Emd Millipore Corporation Micro-incubation systems for microfluidic cell culture and methods
US9206384B2 (en) 2011-12-03 2015-12-08 Emd Millipore Corporation Micro-incubation systems for microfluidic cell culture and methods
US11422125B2 (en) 2015-03-23 2022-08-23 Astellas Institute For Regenerative Medicine Assays for potency of human retinal pigment epithelium (RPE) cells and photoreceptor progenitors
US11680941B2 (en) 2015-03-23 2023-06-20 Astellas Institute For Regenerative Medicine Assays for potency of human retinal pigment epithelium (RPE) cells and photoreceptor progenitors
WO2024057159A1 (fr) * 2022-09-14 2024-03-21 Politecnico Di Milano Système accessible optiquement pour études sur œufs embryonnés

Also Published As

Publication number Publication date
EP1711594A1 (fr) 2006-10-18
US7910369B2 (en) 2011-03-22
EP1711594A4 (fr) 2007-07-11
AU2005205516A1 (en) 2005-07-28
CA2852122A1 (fr) 2005-07-28
US20070067860A1 (en) 2007-03-22
NZ548623A (en) 2010-04-30
CA2552288C (fr) 2015-02-24
IL176641A (en) 2011-02-28
US20140057348A1 (en) 2014-02-27
WO2005068610A1 (fr) 2005-07-28
AU2005205516B2 (en) 2010-12-16
US20060031955A1 (en) 2006-02-09
CA2552288A1 (fr) 2005-07-28
US8597944B2 (en) 2013-12-03
IL176641A0 (en) 2006-10-31
US20110256622A1 (en) 2011-10-20

Similar Documents

Publication Publication Date Title
US7910369B2 (en) Culture systems for ex vivo development
Vassiliev et al. In vitro and in vivo characterization of putative porcine embryonic stem cells
CA2679109C (fr) Derivation de cellules souches embryonnaires
JP2005151907A5 (fr)
Zhang et al. Generation of artificial gamete and embryo from stem cells in reproductive medicine
AU2007248412A1 (en) Derivation of embryonic stem cells and embryo-derived cells
CN106282113B (zh) 一种利用无血清培养基通过转分化获得神经细胞的方法
Parsons et al. Defining conditions for sustaining epiblast pluripotence enables direct induction of clinically-suitable human myocardial grafts from biologics-free human embryonic stem cells
US20170283777A1 (en) Mammalian chimeric complementation
Heo et al. Production of somatic chimera chicks by injection of bone marrow cells into recipient blastoderms
JP2010507373A (ja) 動物血清を含まない培地中で着床前胚から多能性細胞を単離するための方法
JP2005523685A (ja) 体細胞由来胚幹細胞及びそれらの分化子孫
JP2002176973A (ja) 哺乳動物胚性幹細胞とその樹立方法並びにその継代培養方法
CN114369567B (zh) 牛扩展多能性胚胎干细胞的建系方法及培养液
Bhat et al. The role of embryonic stem cells, transcription and growth factors in mammals: A review
WO2005040361A1 (fr) Procede permettant de preparer facilement une cellule souche, et cellule nourriciere utilisee dans ladite cellule souche
Zheng LiMing et al. The state and application of livestock pluripotent stem cells.
Fukunaga et al. Embryonic Stem Cells: A Novel Attractive Research Tool for Germ Cell Development
AU2018220130A1 (en) Derivation of Embryonic Stem Cells and Embryo-Derived Cells
Choi et al. Possibility to establish chicken stem cell from non-germline tissue; detection of colony-forming cells after chicken fibroblast culture and subsequent stem cell characterization
TW200806794A (en) Method of deriving pluripotent stem cells from a single blastomere
AU2016250484A1 (en) Highly efficient methods for reprogramming differentiated cells and for generating animals and embryonic stem cells from reprogammed cells
KR20140043260A (ko) 수정란에 골수세포의 주입을 통한 조류 체세포 카이메라의 제조 방법
AU2014203668A1 (en) Highly efficient methods for reprogramming differentiated cells and for generating animals and embryonic stem cells from reprogammed cells

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION